Aspirin 300 mg/day is effective for treating aspirin‐exacerbated respiratory disease. Issue 11 (14th October 2013)

• Record Type: Journal Article
• Authors: Comert, S.; Celebioglu, E.; Yucel, T.; Erdogan, T.; Karakaya, G.; Onerci, M.; Kalyoncu, A. F.
• Is Part Of: Allergy. Volume 68:Issue 11(2013:Nov.)
• Page Start: 1443
• Page End: 1451
• Publication Date: 2013-10-14
• Subjects: aspirin desensitization treatment -- asthma -- desensitization -- rhinitis; Allergy -- Periodicals; 616.97
• DOI: 10.1111/all.12269
• Languages: English
• ISSNs: 0105-4538

Abstract

Abstract: Background: Aspirin desensitization (AD) treatment at doses of up to 1300 mg/day improves outcomes in aspirin‐exacerbated respiratory disease (AERD). The aim of this study was to investigate the efficacy of aspirin 300 mg/day in the treatment of patients with AERD. Methods: The study included 40 patients diagnosed in our clinic as AERD that were desensitized and treated with aspirin 300 mg/day between December 2005 and December 2012. Changes from the baseline status were analyzed at 1 year and at 3 years of follow‐up. Results: Of the 40 patients included, 24 (60%) were female and median (interquartile range [IQR]) age was 45 (40–51) years. Median (IQR) duration of AD was 31.5 (10.5–48.5) months. In total, 29 patients continued treatment for at least 1 year and 18 patients for at least 3 years. The annual rate of use of systemic corticosteroid regimens, episodes of sinusitis, and surgery was significantly lower both at 1 year ( P = 0.002, P = 0.01, and P < 0.001, respectively) and at 3 years ( P = 0.001, P = 0.03, and P = 0.002, respectively). Significant improvement was observed in the nasal congestion score ( P = 0.01) and sense of smell score ( P = 0.05) at 1 year and in the postnasal drainage score ( P = 0.01) at 3 years. Conclusion: Daily treatment with aspirin 300 mg had beneficial effects in patients with AERD, especially for the control of upper airway disease.